Fig. 1From: Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysisPartitioned survival model diagram. (Note: mTNBC, metastatic triple-negative breast cancer; SG, sacituzumab govitecan; TPC, treatment of physician’s choice; PFS, progression-free survival; PD, progressed disease; P, partitioned survival analysis)Back to article page